<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928304</url>
  </required_header>
  <id_info>
    <org_study_id>14311</org_study_id>
    <nct_id>NCT00928304</nct_id>
  </id_info>
  <brief_title>Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.</brief_title>
  <official_title>An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of BAY94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection of Cerebral ß-Amyloid in Individuals With Down Syndrome Compared to Individuals Without Down Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piramal Imaging SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Piramal Imaging SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting
      cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals
      without DS. Given that individuals with Down Syndrome develop β-amyloid pathology over the
      age of 40, the clinical diagnosis of Down Syndrome will serve as the standard of truth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome</measure>
    <time_frame>100-120 min</time_frame>
    <description>The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity Results in the Down Syndrome Age Subgroups</measure>
    <time_frame>100 - 120 min</time_frame>
    <description>The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Parameters Standard Uptake Value Ratio</measure>
    <time_frame>100 - 120 min p.i.</time_frame>
    <description>The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consistency Between Visual and Quantitative Efficacy</measure>
    <time_frame>100 - 120 min</time_frame>
    <description>For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Amyloid Beta-protein</condition>
  <arm_group>
    <arm_group_label>Florbetaben (BAY94-9172)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetaben (BAY94-9172)</intervention_name>
    <description>300 megabecquerels (MBq) as single IV injection of 2 to 10 mL</description>
    <arm_group_label>Florbetaben (BAY94-9172)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study participants were individuals with DS and healthy volunteers (HVs).

          -  Main inclusion criteria for individuals without DS

               -  &gt;=21 and &lt;= 40 years of age

               -  Mini-Mental State Examination (MMSE) &gt;= 28

               -  Clinical Dementia Rating (CDR) of 0

          -  Main inclusion criteria for individuals with DS

               -  &gt;= 40 years of age

        Exclusion Criteria:

          -  Main exclusion criteria for both groups

               -  Unstable medical or psychiatric condition, study specific screening procedures
                  with the understanding that the patient has the right to withdraw from the study
                  at any time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2014</results_first_posted>
  <disposition_first_submitted>May 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2013</disposition_first_posted>
  <last_update_submitted>January 29, 2014</last_update_submitted>
  <last_update_submitted_qc>January 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloid beta-protein</keyword>
  <keyword>Down Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at two sites in the US.</recruitment_details>
      <pre_assignment_details>A total of 130 subjects were screened. 21 subjects were considered as screen failures and were not enrolled into the study. 9 subjects did not meet the inclusion/exclusion criteria. 10 subjects withdrew their consent. 1 subject was lost to follow-up and 1 subjected exceeded the weight limit for the camera.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Down Syndrome Group</title>
          <description>39 Down Syndrome subjects received Florbetaben (BAY94-9172) : 300 megabecquerels (MBq) single IV injection of 2 to 10 mL</description>
        </group>
        <group group_id="P2">
          <title>Healthy Volunteer Group</title>
          <description>70 healthy volunteer subjects received Florbetaben (BAY94-9172): 300 MBq single IV injection of 2 to 10 mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Down Syndrome subjects and healthy volunteers enrolled into the study were included in the Baseline Analysis Population</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Enrolled in Study</title>
          <description>All Down Syndrome and healthy volunteer subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Down Syndrome Group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Healthy Volunteer Group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome</title>
        <description>The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.</description>
        <time_frame>100-120 min</time_frame>
        <population>All subjects in the down syndrome population and healthy volunteers were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Majority Read</title>
            <description>Majority read of the visual assessment made by 3 independent readers of PET images from all subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome</title>
          <description>The primary variables are sensitivity (percentage of DS subjects positive for cerebral beta-amyloid) and specificity (percentage of healthy volunteers negative for cerebral beta-amyloid) of brain uptake of florbetaben based on the majority read of the visual assessment by three independent blinded readers of PET images obtained 100 to 120 minutes post-injection of florbetaben.</description>
          <population>All subjects in the down syndrome population and healthy volunteers were included in this analysis.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.15" lower_limit="30.51" upper_limit="61.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="100.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity Results in the Down Syndrome Age Subgroups</title>
        <description>The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.</description>
        <time_frame>100 - 120 min</time_frame>
        <population>All Down Syndrome subjects (n=39) were analyzed for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Majority Read (DS-Young)</title>
            <description>Majority Read results for Down Syndrome subjects with age &lt;= 46 yrs</description>
          </group>
          <group group_id="O2">
            <title>Majority Read (DS-Old)</title>
            <description>Majority Read results for Down Syndrome subjects with age &gt;46 yrs</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Results in the Down Syndrome Age Subgroups</title>
          <description>The majority read sensitivity (percentage of DS subjects positive for cerebral beta-amyloid by majority read) was computed for the group of DS subjects with age equal to or below the median age (DS-young) and for DS subjects with age above the median age (DS-old). The median age was 46 yrs, with 3 subjects being exactly 46 yrs old. As defined, these subjects were assigned to the DS-young group.</description>
          <population>All Down Syndrome subjects (n=39) were analyzed for this outcome.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.81" lower_limit="5.59" upper_limit="42.03"/>
                    <measurement group_id="O2" value="72.22" lower_limit="51.53" upper_limit="92.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Parameters Standard Uptake Value Ratio</title>
        <description>The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
        <time_frame>100 - 120 min p.i.</time_frame>
        <population>All Down Syndrome subjects and healthy volunteers enrolled in the study were included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Down Syndrome Group</title>
            <description>Subjects with Down Syndrome enrolled in the study</description>
          </group>
          <group group_id="O2">
            <title>Healthy Volunteer Group</title>
            <description>Healthy volunteers enrolled in the study</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Parameters Standard Uptake Value Ratio</title>
          <description>The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, posterior cingulate, lateral temporal cortex, parietal cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
          <population>All Down Syndrome subjects and healthy volunteers enrolled in the study were included in this analysis</population>
          <units>SUVR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>frontal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.396" spread="0.2488"/>
                    <measurement group_id="O2" value="1.146" spread="0.0749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>posterior cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.525" spread="0.2549"/>
                    <measurement group_id="O2" value="1.329" spread="0.1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lateral temporal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.350" spread="0.2265"/>
                    <measurement group_id="O2" value="1.132" spread="0.0623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>parietal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.391" spread="0.2594"/>
                    <measurement group_id="O2" value="1.138" spread="0.0742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cerebellum, white matter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.730" spread="0.2115"/>
                    <measurement group_id="O2" value="1.769" spread="0.1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consistency Between Visual and Quantitative Efficacy</title>
        <description>For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
        <time_frame>100 - 120 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Down Syndrome PET-positive (Majority Read)</title>
            <description>Down Syndrome subjects positive for cerebral beta-amyloid as determined by majority read</description>
          </group>
          <group group_id="O2">
            <title>Down Syndrome PET-negative (Majority Read)</title>
            <description>Down Syndrome subjects negative for cerebral beta-amyloid as determined by majority read</description>
          </group>
          <group group_id="O3">
            <title>Healthy Volunteer Group</title>
            <description>All healthy volunteers enrolled in the study</description>
          </group>
        </group_list>
        <measure>
          <title>Consistency Between Visual and Quantitative Efficacy</title>
          <description>For a comparison of the results of the visual assessment with the quantitative assessment, descriptive Standardized Uptake Value Ratio (SUVR) statistics were computed separately for DS subjects with an abnormal/normal majority read of the PET scan (DS-PET+/DS-PET-). The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.</description>
          <units>SUVR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>frontal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.566" spread="0.2372"/>
                    <measurement group_id="O2" value="1.249" spread="0.1451"/>
                    <measurement group_id="O3" value="1.146" spread="0.0749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>posterior cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" spread="0.2372"/>
                    <measurement group_id="O2" value="1.438" spread="0.2421"/>
                    <measurement group_id="O3" value="1.329" spread="0.1118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lateral temporal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.498" spread="0.2396"/>
                    <measurement group_id="O2" value="1.223" spread="0.1092"/>
                    <measurement group_id="O3" value="1.132" spread="0.0623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>parietal cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="0.2567"/>
                    <measurement group_id="O2" value="1.250" spread="0.1620"/>
                    <measurement group_id="O3" value="1.138" spread="0.0742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cerebellum, white matter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.698" spread="0.2396"/>
                    <measurement group_id="O2" value="1.758" spread="0.1856"/>
                    <measurement group_id="O3" value="1.769" spread="0.1302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <desc>Adverse event data were collected from Day 1 (baseline) until Day 8 (secondary follow-up visit)</desc>
      <group_list>
        <group group_id="E1">
          <title>Down Syndrome Group</title>
          <description>39 Down Syndrome subjects received Florbetaben (BAY94-9172): 300 MBq single IV injection of 2 to 10 mL</description>
        </group>
        <group group_id="E2">
          <title>Healthy Volunteer Group</title>
          <description>70 healthy volunteer subjects received Florbetaben (BAY94-9172): 300 MBq single IV injection of 2 to 10 mL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juergen Hirschfeld</name_or_title>
      <organization>Piramal Imaging</organization>
      <phone>49 30 461 1246 15</phone>
      <email>juergen.hirschfeld@piramal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

